Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.22.2
Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Contract Assets and Liabilities
The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
June 30, 2022 December 31, 2021
Current pharma contract assets (1)
$ 1,951  $ 1,738 
Long-term pharma contract assets (2)
283  236 
Total pharma contract assets $ 2,234  $ 1,974 
Current pharma capitalized commissions (1)
$ 128  $ 109 
Long-term pharma capitalized commissions (2)
1,139  882 
Total pharma capitalized commissions $ 1,267  $ 991 
Current pharma contract liabilities $ 6,348  $ 5,192 
Long-term pharma contract liabilities (3)
1,121  917 
Total pharma contract liabilities $ 7,469  $ 6,109 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Schedule of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
Clinical Services:
    Client direct billing $ 69,874  $ 63,137  $ 134,888  $ 123,846 
    Commercial Insurance 18,512  20,528  36,800  39,102 
    Medicare and Medicaid 17,167  17,484  32,632  34,634 
    Self-Pay 82  256  106  310 
Total Clinical Services $ 105,635  $ 101,405  $ 204,426  $ 197,892 
Pharma Services: 19,437  20,319  37,815  39,365 
Total Revenue $ 125,072  $ 121,724  $ 242,241  $ 237,257